Literature DB >> 1783570

Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501.

A M Reed1, L Pachman, C Ober.   

Abstract

Juvenile dermatomyositis (JDMS) is an inflammatory disease associated with HLA-DR3. We therefore undertook molecular genetic studies of HLA region genes to determine whether HLA-DR3 itself confers susceptibility to JDMS or whether susceptibility is conferred by alleles in linkage disequilibrium with HLA-DR3. Our results indicate that JDMS is associated with the HLA-DQA1 allele DQA1 *0501 on non-DR3 haplotypes in Caucasian JDMS. Furthermore, the reported of association between the C4A gene deletion and JDMS is likely due to linkage disequilibrium with HLA-DR3.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783570     DOI: 10.1016/0198-8859(91)90085-n

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  24 in total

1.  HLA DQA1*0501 and DRB1*0301 antigens do not independently convey susceptibility to Graves' disease.

Authors:  G Philippou; A Krimitzas; G Kaltsas; E Anastasiou; A Souvatzoglou; M Alevizaki
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

2.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

3.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 4.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 5.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

6.  Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis.

Authors:  M R O'Gorman; V Corrochano; J Roleck; M Donovan; L M Pachman
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 7.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 8.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

Review 9.  Microchimerism in children with rheumatic disorders: what does it mean?

Authors:  Ann M Reed
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

10.  Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Authors:  Timothy B Niewold; Silvia N Kariuki; Gabrielle A Morgan; Sheela Shrestha; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.